Tavexia Lifecare (TAVEXIA) Q2 FY27's Q2 Revenue Plunges 70% as Strategic Pivot Takes Hold
The company's revenue fell sharply year-on-year to ₹5 crore as its traditional trading business contracted ahead of a major pharmaceutical acquisition.
Tavexia Lifecare's Q2 FY27 revenue fell 70% year-on-year to ₹5.04 crore, with a net loss of ₹0.4 crore. The sharp decline comes as the company transitions from trading to pharmaceuticals, backed by a ₹68 crore fundraise plan.
Tavexia Lifecare is navigating a deliberate, capital-intensive shift away from its legacy trading operations. The September quarter results show the cost of that transition, with revenue collapsing year-on-year even as the company lines up funding for its pharmaceutical future.
The numbers tell a story of a business in flux. Revenue fell 70% from the same quarter last year to ₹5.04 crore. The company posted a net loss of ₹0.4 crore, a sharp reversal from a ₹0.66 crore profit in Q2 FY26.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 5.04YoY -70% | 0.65 | 16.84 |
| Profit (₹ Cr) | -0.40YoY -161% | -0.16 | 0.66 |
| Net Profit Margin | -7.9%YoY -303% | -24.8% | 3.9% |
Sequentially, revenue jumped over six-fold from an exceptionally weak ₹0.65 crore in the June quarter. This QoQ rebound, however, only highlights the volatility of its current operations.
The Core Business Recedes
The dramatic annual decline stems from a pullback in its traditional trading and distribution of products like burners and camphor. According to a report by Multibagg.ai, the company is developing a vertically integrated pharmaceutical platform while its core trading business recedes.
This strategic pivot is capital-heavy. Interest expense surged 400% year-on-year, reflecting the cost of funding this shift. Other income also rose sharply to ₹0.49 crore, which InvestyWise linked to board approval for a ₹68 crore fundraise to finance an acquisition.
Funding the Pharmaceutical Future
The quarter's financials are a backdrop to a larger corporate story. In October, the board approved acquiring a 60% controlling stake in Meyonex Pharmaceuticals for ₹67.19 crore, as reported by StockFin.ai. The deal grants immediate manufacturing capacity in Maharashtra's MIDC Tarapur.
Management has initiated plans to raise up to ₹68 crore through equity or convertible instruments to fund this move. The acquisition is central to Tavexia's rebranding and expansion into active pharmaceutical ingredients (APIs), formulations, and contract manufacturing.
A Valuation Built on Promise
With trailing-twelve-month revenue of ₹19.88 crore and a net loss of ₹1.96 crore, the stock trades at a price-to-earnings multiple of 74. This is a 64% premium to the industry PE of 45.2, pricing in the success of a pharma foray that has yet to contribute.
The market appears to be valuing the blueprint, not the current operations. The share price was flat at ₹1.17 around the results date, with no immediate analyst reaction noted in the research.
Key Points
- Revenue fell 70% year-on-year as the company's legacy trading business contracted sharply.
- The company is pivoting to pharmaceuticals, backed by a planned ₹68 crore fundraise for the Meyonex acquisition.
- Interest costs rose 400% YoY, reflecting higher borrowing to fund the strategic shift.
- The stock trades at a significant earnings premium, valuing the future pharma platform over current weak profits.
Hexa Perspective
Tavexia Lifecare's quarter confirms it is a company between two lives. The old trading model is winding down, creating a deep earnings hole. The new pharmaceutical ambition is funded but unproven, carrying execution and integration risk. Investors are being asked to fund a transition. The next few quarters will show if the Meyonex acquisition can generate revenue and profit at a scale that justifies the current valuation premium and covers the cost of capital.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
